RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Content

Ivanishcheva Irina Gennadievna
Ivanishcheva Irina Gennadievna

Education

Two higher educations: MIET and GUU with a degree in jurisprudence.

Career

2002-2006

In 2002, she began her career at the Russian representative office of AstraZeneca. In 2006, she began working in the legal department, which she headed a year later.

Thanks to her efforts, the work of the legal department was built, which provides comprehensive support in the field of corporate, commercial, labor and antitrust law to the company's business in Russia and Eurasia, the company's website says.

2016-2019

In 2016, AstraZeneca was appointed to the position of Director of Corporate Relations and Legal Affairs for the Russia and Eurasia region. In this role, she began to provide legal support, as well as be responsible for working with state bodies and the development of internal and external communications in Russia and Eurasia.

In 2018, she was responsible for interaction with government agencies in the Middle East and Africa region. In 2019, she was appointed to the company as director of regulatory policy and international markets.

2021

On June 1, 2022, Irina Ivanishcheva began working in the Russian office of Novo Nordisk as director for legal issues, compliance and quality system. Prior to that, she worked at AstraZeneca as Director of Corporate Relations and Legal Affairs for Russia and Eurasia.

2022: Appointment as Head of Novo Nordisk Office in Russia and Belarus

At the end of May 2022, it became known about the appointment of Irina Ivanishcheva as vice president and general manager of the Novo Nordisk branch in Russia and Belarus.

As noted in the company, Ivanishcheva at the time of appointment as the head of the office worked in it for about a year, and during this time she demonstrated high professional and leadership qualities, ensuring the highest standards in her area of ​ ​ responsibility. In addition, she successfully defended the interests of the company on legal issues, Novo Nordisk said.[1]

Notes